biohacking$bioLLM CA: TBA

database / nootropic

Cerebrolysin

in clinical study nootropic nervous sequence not characterised

Research reference only. The observations below are recorded in the cited literature. Nothing here is advice or a recommendation, and no dosing information is published on this site.

Sequence

Primary structure not characterised in the public records this index draws on. Nothing is shown rather than something invented.

A porcine brain-derived peptide mixture, not a single defined molecule — no sequence exists to report.

Molecular data

Chemical fields come from the PubChem compound record; computed values are derived from the sequence shown above.
molecular formulanot characterised
molecular weightnot characterised
computed backbone massnot characterised
lengthnot characterised
net charge (pH 7.4)not characterised
mean hydropathynot characterised
half-lifenot characterised
delivery routeintravenous, intramuscular
PubChem CIDnot characterised
PDBnot characterised
UniProt parentnot characterised

Mechanism

Peptide preparation studied for neurotrophic-like activity.

Reported targets: not established

Experimental structure

No experimental structure of this peptide is deposited in the PDB. Nothing is rendered here — a predicted fold would not be a structure, and this site does not draw one.

Reported effects

Each row is an outcome described in the literature indexed for this peptide. Reported in the cited work — not a claim, not a recommendation.

Reported observations and the corpus they are drawn from.
reported outcomewhere it appears
cognitive outcomes in trialsVery Early Short-Course Cerebrolysin After Tenecteplase and Mechanical Throm… Case reports in neurological medicine 2026
stroke-recovery outcomes in trialsAdjunctive Cerebrolysin therapy following mechanical thrombectomy for acute … Journal of medicine and life 2026

Registered trials

Records from ClinicalTrials.gov. Listed for reference — this project sponsors no trial and is not involved in any of them.
NCTtitlestatusphase
NCT05124353Early Administration of Cerebrolysin on the Outcome of Patients With Acute Stroke UndergoingUNKNOWNPHASE2, PHASE3
NCT06897176Effects of Cerebrolysin on Language Ability in Non-fluent Aphasia Patients After Stroke: A RRECRUITINGPHASE4
NCT06677502Cerebrolysin in Critically Ill Patients With DeliriumENROLLING_BY_INVITATIONNA
NCT06273020Effect of Cerebrolysin on the Blood Brain Barrier in Patients With Diabetes and Ischemic StrUNKNOWNPHASE4
NCT01787123Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of CerCOMPLETEDPHASE2, PHASE3

Literature (8)

Very Early Short-Course Cerebrolysin After Tenecteplase and Mechanical Thrombectomy: A Case Report — Case reports in neurological medicine 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 42666484 · DOI 10.1155/crnm/9962315

Adjunctive Cerebrolysin therapy following mechanical thrombectomy for acute basilar artery occlusion: a case report — Journal of medicine and life 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 42602665 · DOI 10.25122/jml-2026-0081

ABSTRACT NUMBER: ESOC2026A822 VIRTUAL REALITY NEURORREHABILITATION IN ACUTE STROKE PATIENTS AND THE ADD-ON EFFECT OF CEREBROLYSIN — European stroke journal 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

open access ↗

Cerebrolysin as an adjunct to speech-language therapy in post-stroke Wernicke's aphasia: a case report — Journal of medicine and life 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

publisher record ↗ · PMID 42602663 · DOI 10.25122/jml-2026-0057

ABSTRACT NUMBER: ESOC2026A562 CEREBROLYSIN AFTER ENDOVASCULAR THROMBECTOMY IN STROKE: 12-MONTH FUNCTIONAL OUTCOMES IN A PROPENSITY-MATCHED COHORT — European stroke journal 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

open access ↗

ABSTRACT NUMBER: ESOC2026A632 CYTOPROTECTIVE EFFICACY OF CEREBROLYSIN IN PATIENTS WITH RESIDUAL POST-THROMBECTOMY PERFUSION DEFICITS: A PROOF-OF-CONCEPT STUDY — European stroke journal 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

open access ↗

ABSTRACT NUMBER: ESOC2026A102 META-ANALYSIS: THE EFFECT OF CEREBROLYSIN COMBINED WITH SPEECH THERAPY ON NONFLUENT APHASIA RECOVERY AFTER ISCHEMIC STROKE — European stroke journal 2026

abstract not reproduced — this record is not open-access, so it is linked rather than copied.

open access ↗

Exosomes Released by Cerebrolysin-Treated Cerebral Endothelial Cells Reverse Fibrin- or tPA-Impaired Endothelial Cell Permeability — Cells 2026

Cerebrolysin has a salutary effect on impaired cerebral endothelial cell (CEC) permeability. Using an in vitro endothelial permeability assay, the present study tested the hypothesis that exosomes released by Cerebrolysin-treated CECs (Cerebro-Exos) have a robust therapeutic effect on dysfunctional CECs. Stoichiometric analysis showed marked differences in cargo profiles between Cerebro-Exos and exosomes derived from CECs without Cerebrolysin treatment (Naïve-Exos), in which Cerebro-Exos were highly enriched with metabolic and tight junction related proteins compared to Naïve-Exos. Cerebro-Exos had a superior effect compared to Naïve-Exos on restoring CEC integrity impaired by fibrin and tissue plasminogen activator (tPA). Treatment of fibrin- and tPA-challenged CECs with Cerebro-Exos robustly reduced fibrin- and tPA-augmented proteins involved in inflammation and coagulation and substan…

open access ↗ · PMID 42193943 · DOI 10.3390/cells15100934

Related

AOD-9604

metabolic · 8 citations

HGH Fragment 176-191

metabolic · 2 citations

Vilon

longevity · 8 citations

Epitalon

longevity · 8 citations

Pinealon

longevity · 8 citations

Cortagen

nootropic · 5 citations